Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma

Overview of attention for article published in Drug Design, Development and Therapy, January 2018

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 35 Dimensions

Readers on

mendeley: 67 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 35 publications that cite this research output.

35

The most recent citing publications are shown below. View all 35 publications that cite this research output on Dimensions.

TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy

Article in Therapeutic Advances in Medical Oncology (January 2024)

Noninvasive PET imaging of tumor PD-L1 expression with 64Cu-labeled Durvalumab.

Article in Am j nucl med mol imaging (January 2024)

Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics

Article in Clinical and Experimental Medicine (October 2023)